The platform technology is based on the induction of polyclonal antibodies to selected proteins of individual viruses in animals. These antibodies are subsequently purified and formulated for administration to humans. ABIVAX’s POLYCLONAL ANTIBODIES PLATFORM has led to the generation of neutralizing antibodies against different viruses and the first application is for the prevention and treatment of Ebola virus infections. ABX544 will go into preclinical development during Q2 2017.